Your browser doesn't support javascript.
loading
Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR.
Vizoso, Miguel; Ferreira, Humberto J; Lopez-Serra, Paula; Carmona, F Javier; Martínez-Cardús, Anna; Girotti, Maria Romina; Villanueva, Alberto; Guil, Sonia; Moutinho, Catia; Liz, Julia; Portela, Anna; Heyn, Holger; Moran, Sebastian; Vidal, August; Martinez-Iniesta, Maria; Manzano, Jose L; Fernandez-Figueras, Maria Teresa; Elez, Elena; Muñoz-Couselo, Eva; Botella-Estrada, Rafael; Berrocal, Alfonso; Pontén, Fredrik; Oord, Joost van den; Gallagher, William M; Frederick, Dennie T; Flaherty, Keith T; McDermott, Ultan; Lorigan, Paul; Marais, Richard; Esteller, Manel.
Afiliação
  • Vizoso M; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Ferreira HJ; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Lopez-Serra P; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Carmona FJ; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Martínez-Cardús A; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Girotti MR; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester, UK.
  • Villanueva A; Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Guil S; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Moutinho C; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Liz J; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Portela A; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Heyn H; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Moran S; Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Vidal A; Department of Pathological Anatomy, Bellvitge University Hospital, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Martinez-Iniesta M; Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
  • Manzano JL; Medical Oncology Service, Catalan Institute of Oncology, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain.
  • Fernandez-Figueras MT; Pathology Department, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain.
  • Elez E; Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Catalonia, Spain.
  • Muñoz-Couselo E; Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Catalonia, Spain.
  • Botella-Estrada R; Dermatology Service, Hospital La Fe, Universidad de Valencia, Valencia, Spain.
  • Berrocal A; Medical Oncology Service, Hospital General, Valencia, Spain.
  • Pontén F; Department of Pathology, University Hospital of Uppsala, Uppsala, Sweden.
  • Oord Jv; Translational Cell &Tissue Pathology, Katholieke Universiteit Leuven, Leuven, Belgium.
  • Gallagher WM; University College Dublin School of Biomolecular and Biomedical Science, University College Dublin Conway Institute, University College Dublin, Belfield, Dublin, Ireland.
  • Frederick DT; Center for Melanoma, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Flaherty KT; Center for Melanoma, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • McDermott U; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.
  • Lorigan P; University of Manchester, Christie National Health Service Foundation Trust, Manchester, UK.
  • Marais R; Molecular Oncology Group, Cancer Research UK Manchester Institute, Manchester, UK.
  • Esteller M; 1] Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain. [2] Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Catalonia, Spain. [3] Institucio Catalana de Recerca i Estudis Avançats,
Nat Med ; 21(7): 741-50, 2015 Jul.
Article em En | MEDLINE | ID: mdl-26030178
Metastasis is responsible for most cancer-related deaths, and, among common tumor types, melanoma is one with great potential to metastasize. Here we study the contribution of epigenetic changes to the dissemination process by analyzing the changes that occur at the DNA methylation level between primary cancer cells and metastases. We found a hypomethylation event that reactivates a cryptic transcript of the Rab GTPase activating protein TBC1D16 (TBC1D16-47 kDa; referred to hereafter as TBC1D16-47KD) to be a characteristic feature of the metastatic cascade. This short isoform of TBC1D16 exacerbates melanoma growth and metastasis both in vitro and in vivo. By combining immunoprecipitation and mass spectrometry, we identified RAB5C as a new TBC1D16 target and showed that it regulates EGFR in melanoma cells. We also found that epigenetic reactivation of TBC1D16-47KD is associated with poor clinical outcome in melanoma, while conferring greater sensitivity to BRAF and MEK inhibitors.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Progressão da Doença / Proteínas Ativadoras de GTPase / Epigênese Genética / Receptores ErbB / Melanoma Idioma: En Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Progressão da Doença / Proteínas Ativadoras de GTPase / Epigênese Genética / Receptores ErbB / Melanoma Idioma: En Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Espanha